

**“Innovations in Personalized Oncology: A Case-Based Approach”
Third Annual MSK Cancer Alliance Symposium**

Friday, May 4th, 2018 – Morning Sessions		
Time	Topics	Speakers
8:00 – 8:10 AM	Opening Remarks	David Pfister, MD
8:10 – 8:35 AM	Keynote – Evolving predictors of response for immunotherapy	Timothy Chan, MD
8:35 – 9:20 AM	Non-Hodgkin’s Lymphoma Moderator: Andrew Zelenetz, MD, PhD	
	Case: 56-year-old female with a biopsy-proven composite of dominant follicular lymphoma, grade 1-2, and a component of SLL/CLL	
	Dramatic response to mocetinostat in a patient with a CREBP/EP300 mutation	Connie Batlevi, MD, PhD
	Is observation still an appropriate option for treatment of indolent lymphoma?	Andrew Zelenetz, MD, PhD
	Checkpoint inhibitors in primary mediastinal large cell lymphoma	Craig Moskowitz, MD
	APP role in the conduct of a phase I trial of a novel PI3K inhibitor	Jason Carter, PA-C
9:20 – 10:05 AM	Prostate Cancer Moderator: Philip Kantoff, MD	
	Case: 65-year-old male with back pain, elevated PSA and extensively positive bone scan	
	Treatment versus active surveillance for good risk prostate cancer: available tests their performance	James Eastham, MD
	Approach to a patient with high-risk localized prostate cancer	Sean McBride, MD
	Approach to a patient with metastatic hormone-sensitive prostate cancer: what data shows us?	Michael Morris, MD
	How to use genetic data to generate a rational approach for patients with metastatic castration-resistant prostate cancer	Philip Kantoff, MD
10:05 – 10:30 AM	Break	
10:30 – 11:15 AM	Pediatric Cancers Moderator: Suzanne Wolden, MD	
	Case: 18-year-old female with desmoplastic medulloblastoma	
	Role of proton craniospinal RT	Matthew Hall, MD
	Molecular subtyping of medulloblastoma	Marc Rosenblum, MD
	Chemotherapy strategy; outcomes for adults	Kevin De Braganca, MD
	Long-term neuropsychiatric outcomes in survivors of medulloblastoma	Stephen Sands, PsyD
11:15 – 12:00 PM	Gynecological Cancers Moderator: Paul Sabbatini, MD	
	Case: 45-year-old female with stage IIIC optimally debulked ovarian cancer, recurrent	
	IP versus IV dose-dense versus IV three weekly treatment	William Tew, MD
	Resection at recurrence: when is it right to do it?	Ginger Gardner, MD
	The role of robotic resection	Martin Martino, MD
	PARP maintenance for everyone?	Roisin O’Cearbhaill, MD
	Cold cap use to prevent hair loss	Mikel Ross, RN
12:00 – 1:00 PM	Lunch	

Friday, May 4th, 2018 – Afternoon Sessions

Time	Topics	Speakers
1:00 – 1:25 PM	Keynote – Checkpoint inhibitors: symptom assessment and management from a nursing perspective	Ruth-Ann Gordon, MSN, FNP-BC, OCN
1:25 – 2:10 PM	Thyroid Cancer Moderator: Michael Tuttle, MD Case: 71-year-old male with <i>BRAF</i> -mutated PTC with anaplastic transformation	
	Initial and dynamic risk stratification: using tumor volume doubling times and FDG-PET to predict outcomes in the setting of distant metastases	Mona Sabra, MD
	Novel systemic therapy options for RAI-refractory and anaplastic thyroid cancer	Alan Ho, MD, PhD
	Understanding patient and family safety issues that are critical to effective implementation of an outpatient RAI therapy program	Lawrence Dauer, PhD
	Utilizing treatment algorithms for the management of expected dermatological toxicities to multitargeted kinase inhibitors	Lauren Evans, MSN, OCN, CCRP
2:10 – 2:55 PM	Colorectal Cancer Moderator: Leonard Saltz, MD Case: 68-year-old woman with metastatic colon cancer, mismatch-repair proficient, RAS wild-type, <i>BRAF</i> V600E-mutated	
	Molecular profiling of colorectal cancer: the impact of MSK IMPACT	Rona Yaeger, MD
	Systemic therapy for local-regional disease and local-regional therapy for metastatic disease	Andrea Cercek, MD
	Operational aspects of non-operative management in locally advanced rectal cancer	J. Joshua Smith, MD, PhD
	ERAS protocols for colorectal cancers	Robert J. Sinnott, MD
2:55 – 3:20 PM	Break	
3:20 – 4:05 PM	Lung Cancer Moderator: Bernard Park, MD Case: 56-year-old female, former smoker with stage IV lung cancer to brain and adrenal gland	
	Treatment of oligometastatic non-small cell lung cancer	Helena Yu, MD
	Lung cancer stigma	Smita Banerjee, PhD
	Role of minimally-invasive surgery in the multimodality treatment of advanced lung cancer	Mario Katigbak, MD
	Optimizing antiemetic use	John Timoney, PharmD
	Emerging role of liquid biopsy	Bob Li, MD, MPH
4:05 – 4:50 PM	Breast Cancer Moderator: Larry Norton, MD Case: 49-year-old female with unknown family history, history of 1.1 cm node-negative, high-grade triple-negative primary breast cancer s/p lumpectomy and radiation therapy; now with a contralateral primary, also triple-negative, and metastatic disease	
	Breast cancer treatment with PARP inhibitors	Tiffany Traina, MD
	MSK RISE program	Melissa Pilewskie, MD
	Breast imaging	Elizabeth Morris, MD
	Proton therapy for breast cancer	Marcio Fagundes, MD
	Patient-reported outcomes and survival	Peter Yu, MD
4:50 – 5:00 PM	Concluding Remarks	David Pfister, MD